Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Overview - The company is experiencing a significant year of change and transition, with a focus on pivotal data for a PROTAC, specifically vepdegestrant [1] Company Developments - The first pivotal data for vepdegestrant was positive, but the market and Pfizer's reaction indicated it was not positive enough [1][2] - The mixed response to the positive data has led to a series of next steps for the company, particularly in light of a decline in stock price [2]